| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,700,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,760,286 |
1,799,474 |
| Total Buy Value |
$0 |
$0 |
$10,116,973 |
$10,305,319 |
| Total People Bought |
0 |
0 |
5 |
5 |
| Total Buy Transactions |
0 |
0 |
7 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
13,280 |
| Total Sell Value |
$0 |
$0 |
$0 |
$81,274 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chardonnet Laurent |
Chief Financial Officer |
• – – |
2021-12-13 |
4 |
A |
$12.28 |
$61,400 |
D/D |
5,000 |
8,000 |
|
- |
|
| Vaddi Krishna |
President, CEO |
• • – |
2021-12-13 |
4 |
A |
$12.13 |
$97,035 |
D/D |
8,000 |
1,053,519 |
|
- |
|
| Morosini Deborah |
EVP, Chief of Clinical Affairs |
• – – |
2021-11-16 |
4 |
AS |
$15.87 |
$456,532 |
D/D |
(28,751) |
444 |
|
- |
|
| Morosini Deborah |
EVP, Chief of Clinical Affairs |
• – – |
2021-11-16 |
4 |
OE |
$12.85 |
$369,450 |
D/D |
28,751 |
29,195 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-10-05 |
4 |
AS |
$30.26 |
$464,350 |
D/D |
(15,000) |
0 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-10-05 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-09-07 |
4 |
AS |
$35.91 |
$550,283 |
D/D |
(15,000) |
0 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-09-07 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
| Pierce Christopher |
EVP and Chief of Business Oper |
• – – |
2021-09-02 |
4 |
AS |
$40.29 |
$708,493 |
D/D |
(17,000) |
3,750 |
|
- |
|
| Pierce Christopher |
EVP and Chief of Business Oper |
• – – |
2021-09-02 |
4 |
OE |
$12.85 |
$218,450 |
D/D |
17,000 |
20,750 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-27 |
4 |
AS |
$35.32 |
$215,967 |
D/D |
(6,014) |
172,920 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-27 |
4 |
OE |
$1.43 |
$8,600 |
D/D |
6,014 |
178,934 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-26 |
4 |
AS |
$35.19 |
$59,819 |
D/D |
(1,700) |
172,920 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-26 |
4 |
OE |
$1.43 |
$2,431 |
D/D |
1,700 |
174,620 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-13 |
4 |
AS |
$35.07 |
$80,161 |
D/D |
(2,286) |
172,920 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-08-13 |
4 |
OE |
$1.43 |
$3,526 |
D/D |
2,286 |
175,206 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-08-05 |
4 |
AS |
$29.93 |
$466,394 |
D/D |
(15,000) |
0 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-08-05 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-07-27 |
4 |
AS |
$35.45 |
$709,380 |
D/D |
(20,000) |
172,920 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-07-27 |
4 |
OE |
$1.43 |
$28,600 |
D/D |
20,000 |
192,920 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-07-06 |
4 |
AS |
$27.17 |
$412,107 |
D/D |
(15,000) |
0 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-07-06 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-06-07 |
4 |
AS |
$30.35 |
$486,622 |
D/D |
(15,000) |
0 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2021-06-07 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
| Piper Brian |
Chief Financial Officer |
• – – |
2021-05-25 |
4 |
AS |
$33.53 |
$285,537 |
D/D |
(8,333) |
0 |
|
- |
|
100 Records found
|
|
Page 2 of 4 |
|
|
